AUSTIN, Texas--(BUSINESS WIRE)--Maxwell Biosciences, the biotechnology company behind the CLAROMER™ brand anti-infective drug platform, today announced Dr. John Lord has been appointed vice president, Research and Development. Dr. Lord will serve on Maxwell Bioscience’s Executive Committee, reporting to chief executive officer Joshua McClure.
“We are excited to welcome Dr. Lord to Maxwell as we prepare to advance the first of our drug candidates toward clinical trials. John’s track record in the pharmaceutical industry and work building Savara Pharmaceuticals will be instrumental as we continue to grow as a biotech company and advance our pipeline,” said McClure.
Dr. Lord is a 25 year veteran of the pharmaceutical industry. Most recently, Dr. Lord served as senior vice president, Head of Research and Development and Head of the Hørsholm, Denmark based site focused on orphan lung diseases. Dr. Lord joined Savara in 2010 and was a key member of the leadership team that successfully took the company public in July 2018. During his tenure at Savara, Dr. Lord brought a strong focus on scientific integrity, data analysis and quality.
Dr. Lord’s career includes key roles at Nektar Therapeutics and Rhône-Poulenc Rorer. Dr. Lord brings broad product development experience, strong R&D leadership and an ability to develop strong biotech science teams to his role at Maxwell. He has also helped biotech companies move from preclinical to commercial stages and is experienced in peptide and small molecule platform development.
“I am excited to be joining the Maxwell Biosciences team at such an important time. Maxwell has identified a potentially groundbreaking drug platform with the potential to profoundly impact global health,” said Dr. Lord. “I look forward to contributing by driving a world-class R&D program and doing everything required to develop these unique products and to get them to patients.”
Dr. Lord holds a Ph.D. in Pharmacy from University of Bath.
To learn more about Maxwell Biosciences, please visit the company’s corporate website.
About Maxwell Biosciences
Founded in 2016, Maxwell Biosciences develops Drugs designed to be effective against rapidly evolving, widespread viruses. Maxwell’s CLAROMER™ brand anti-infective platform is able to create stabilized cathelicidins which peer-reviewed studies have shown destroy a broad spectrum of viruses. The virucidal mechanism of action is well illustrated in published studies including imaging of viral structures. They have been shown in preclinical studies to destroy a broad spectrum of viruses including rapidly evolving novel Coronavirus strains, MERS, Hepatitis B and C, Rhinovirus, Herpes Simplex Virus and Influenza A virus. They have also been shown to be well tolerated in human tissues and in vivo animal models. Maxwell’s technology is protected by granted patents and is led by a world-class team of experienced life sciences executives.